SAN DIEGO, May 6, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, today announced that it will report its results for the first quarter ended March 31, 2014 on Tuesday, May 13, 2014. The company will also hold a live investor conference call and webcast at 4:30pm Eastern/1:30pm Pacific on Tuesday, May 13, 2014.
Help employers find you! Check out all the jobs and post your resume.